TopFunds

Idexx Laboratories

NASDAQ: IDXX

Stock price

550.01 USD

(+0%) TODAY

Health Care EquipmentMedical - Diagnostics & ResearchInvestable Universe

Financial Performance

Share

5Y price score: (26)

Help

The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.

A score of 100 indicates that the stock did as well as the S&P 500 Index.

A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.

10Y return: 400.4%

DATE RANGE:

US$ Per
Share

    Time scale:

    By default your notes are visible only to you.

    518.5

    52-week range

    769.9

    550.01

    Your model inputs

    Required return / cost of capital
    %
    FCFF terminal growth rate
    %

    Your fair value & Margin of safety

    To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.

    Forecast:

    Valuation

    Free Cash Flow Yield

    Help
    FCF Yield TTM = Trailing Twelve Months free cash flow per share / current market price per shareLearn more

    2.8 %

    Dividend Yield TTM

    -

    Market cap $

    $ 43,386

    Price / Earnings TTM

    Help
    P/E TTM = current market price per share / Trailing Twelve Months diluted earnings per shareLearn more

    39

    Price / Book TTM

    27.3

    PEG TTM

    Help
    Price/Earnings-to-Growth ratio = P/E TTM divided by most recent annual diluted earnings per share growth rateLearn more

    2.5

    Earnings growth and return

    LTM

    5YR

    10YR

    Total return (price & dividends)

    (14.2) %

    (18.7) %

    400.4 %

    Free cash flow per share growth

    113.5 %

    109.5 %

    816.3 %

    Earnings per share growth

    15.4 %

    94.9 %

    538 %

    Founded: 1,983

    Employees: 11,000

    Business Summary:IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.

    Fair Value Reference Estimate

    Latest Earnings Call Takeaways

    2026 Q2 (Aug 4, 2026)

    1) Strategy & Leadership
    - IDEXX Laboratories demonstrated strong execution in Q2 2026, focusing on expanding diagnostic utilization and enhancing their innovation pipeline.
    - The company is investing in commercial capabilities, expanding field presence in four international countries and targeted additions in the U.S.
    - CEO Mike Erickson emphasized the importance of diagnostics in veterinary practices, particularly for aging pets, which is driving demand for IDEXX's products.

    2) Financial & Segment Results
    - Q2 revenue increased approximately 10% YoY, with organic growth of 9%, driven by over 10% growth in CAG Diagnostics recurring revenues.
    - Operating profit grew 12%, with an operating margin of 35% and EPS of $4.27, reflecting a 15% increase on a comparable basis.
    - IDEXX raised its full-year revenue guidance to $4,700 million - $4,745 million, with an organic growth outlook of 8.5% to 9.7%.
    - CAG Diagnostics recurring revenue growth is projected at 9.5% to 10.7%, supported by strong volume and pricing realization.

    3) Problems / Headwinds
    - U.S. same-store clinical visits declined by 1.3%, with wellness visits down nearly 3%, indicating pressure on discretionary veterinary services.
    - Economic factors, such as inflation and rising living costs, are affecting consumer spending on veterinary care, particularly for wellness visits.
    - Foreign currency fluctuations are expected to create a $15 million headwind on reported revenues.

    4) Operational or Product Plans
    - IDEXX is advancing its product innovations, including the inVue Dx platform and the Cancer Dx test, which are expected to enhance diagnostic capabilities and drive growth.
    - The rollout of the Fine Needle Aspiration (FNA) application is progressing well, with plans for broader availability by year-end, potentially increasing consumable revenue.
    - The company is also expanding its Reference Laboratory offerings, with new tests like the Fecal Dx antigen testing platform and additional cancer detection capabilities.

    5) Guidance & Outlook / Investor Angle
    - IDEXX is optimistic about the second half of 2026, expecting continued strong growth in CAG Diagnostics recurring revenues and maintaining high customer loyalty.
    - The company is increasing its full-year EPS outlook to $14.69 - $14.94 per share, reflecting operational performance improvements.
    - Upcoming product launches and innovations are anticipated to support growth, despite the challenges posed by declining clinical visits.

    Bottom line: IDEXX Laboratories is positioned for continued growth through strategic investments in innovation and commercial capabilities, despite facing headwinds from declining clinical visits and economic pressures. The company's strong financial performance and optimistic outlook make it an attractive option for shareholders.

    Annual Reports, Presentations And IR Contacts

    Go to the website
    Annual report links (10K)
    2025202420232022202120202019201820172016

    Idexx Laboratories — Financial Overview, Stock Price, Market Cap

    Idexx Laboratories is a company. Founded in 1983. As of August 26, 2026, the company's market capitalization is $43386438830 with a current stock price of $550.01.